In non-small cell lung cancer, EZH2 upregulates the expression of PD-L1 through HIF-1α, so the combination of HIF-1 inhibitors and immunotherapy may have a more substantial therapeutic effect (135). The gene discussed is HIF1A; the disease is non-small cell lung carcinoma.